Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05774288
Other study ID # TB-CM01-P-275
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date June 8, 2023
Est. completion date June 30, 2029

Study information

Verified date August 2023
Source Lifetech Scientific (Shenzhen) Co., Ltd.
Contact Xiangbin Pan, Doctor
Phone 13811763898
Email xiangbin428@hotmail.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

To evaluate the performance of Cera™ patent foramen ovale occluders developed by Lifetech Scientific (Shenzhen) Co., LTD;


Description:

The purpose of this prospective, multi-center, randomized, controlled non-inferiority clinical trial was to evaluate the safety and efficacy of Cera™ patent foramen ovale occluders developed by Lifetech Scientific (Shenzhen) Co., LTD for the treatment of cryptogenic stroke complicated with patent foramen ovale. The study required the implant to follow instructions strictly.


Recruitment information / eligibility

Status Recruiting
Enrollment 244
Est. completion date June 30, 2029
Est. primary completion date April 30, 2025
Accepts healthy volunteers No
Gender All
Age group 18 Years to 60 Years
Eligibility Inclusion Criteria: 1. Patients aged 18-60 years; 2. Be able to understand the purpose of the experiment, voluntarily participate in the experiment and sign the informed consent; 3. Patent foramen ovale was confirmed by at least one of the following conditions exists: 1. Patent foramen ovale was confirmed by Transthoracic echocardiography (TTE) or Transesophageal echocardiography (TEE); 2. The presence of medium or large right-to-left shunt was confirmed by Right-heart acoustic contrast (cTTE or cTCD); 4. It meets the clinical status of patent foramen ovale plugging indication, and at least one of the following conditions exists: 1. Cryptogenic stroke complicated with patent foramen ovale, combined with one or more clinical risk factors; 2. Cryptogenic stroke complicated with patent foramen ovale, combined with one or more anatomical risk factors of patent foramen ovale; 3. Cryptogenic stroke complicated with patent foramen ovale, with clear deep vein thrombosis or pulmonary embolism, and not suitable for anticoagulant therapy; 4. Cryptogenic stroke complicated with patent foramen ovale, but still recurred with antiplatelet or anticoagulant therapy. Exclusion Criteria: 1. Carotid atherosclerotic stenosis was determined by the investigator based on CT or vascular ultrasound (> 50%); 2. Large cerebral infarction occurred within 4 weeks (MR/CT or DWI image ASPECTS score <6 points or infarction volume =70 ml or infarction area > 1/3 middle cerebral artery blood supply area); 3. Patients with intracardiac thrombosis or tumor, intracardiac vegetations; 4. Acute myocardial infarction or unstable angina within 6 months; 5. Left ventricular aneurysm formation or left ventricular wall movement disorder; 6. Mitral/aortic disease: including mitral stenosis or severe mitral regurgitation of any cause, severe aortic stenosis or severe aortic regurgitation, mitral or aortic valve vegetations or prior valve replacement surgery; 7. Dilated cardiomyopathy, LVEF < 35%, or other severe heart failure; 8. Patients with right-to-left shunt due to other causes, including atrial septal defect or perforated diaphragm; 9. Atrial fibrillation/atrial flutter (chronic or intermittent); 10. Pregnant or planning to become pregnant during the trial; 11. Patients with active endocarditis or other untreated infections or other hemorrhagic diseases; 12. Pulmonary hypertension or patent foramen ovale was a special channel; 13. Liver and kidney function impairment (ALT or AST > 3 times the upper limit of normal value, serum creatinine (Cr) > 2 times the upper limit of normal value); 14. Uncontrolled hypertension (> 180/100 mmHg); 15. Contraindication of antiplatelet or anticoagulant therapy, such as severe bleeding within 3 months, obvious retinopathy, history of other intracranial bleeding, and obvious intracranial diseases; 16. Coronary heart disease, hypertension, diabetes and other vascular diseases that are poorly controlled by drugs or other means; 17. The investigator determined that the patient was not suitable for implantation of PFO occluder (for example, the diameter of the base of the atrial septal tumor =25mm and the size of the foramen ovale =5mm) or the patient has contraindications for implantation of PFO occluder; 18. Thrombosis exists at the location or route of implantation; 19. Malignant neoplasms or other diseases with a life expectancy of less than 2 years; 20. Patients who could not be followed up during the trial; 21. Participate in clinical trials of other drugs or medical devices within three months.

Study Design


Intervention

Device:
Cera™ patent foramen ovale occluders
Patients who meet all the inclusion criteria and don't meet the exclusion criteria will be implanted with the Cera™ patent foramen ovale occluders according to the INSTRUCTIONS for Use (IFU).
Another patent foramen ovale occluders
Patients who meet all the inclusion criteria and don't meet the exclusion criteria will be implanted with the Another patent foramen ovale occluders according to the INSTRUCTIONS for Use (IFU).

Locations

Country Name City State
China Fuwai Hospital ,CAMS&PUMC BeiJing Beijing
China Peking University First Hospital Beijing Beijing
China The First Hospital Of JiLin Universitv Changchun Jilin
China The Second XiangYa Hospital of Central South University Changsha Hunan
China The Third XiangYa Hospital of Central South University Changsha Hunan
China The First Affiliated Hospital, Sun Yat-sen University Guangzhou Guangdong
China Zhejiang Provincial People's Hospital Hangzhou Zhejiang
China Qilu Hospitalof Shandong University JInan Shandong
China The First Affiliated Hospital of Shandong First Medical University (Shandong Provincial Qianfoshan Hospital) Jinan Shandong
China Fuwai Yunnan Cardiovascular Hospital Kunming Yunnan
China Meizhou people'Hospital Meizhou Guangdong
China The First Affiliated Hospital of Ningbo University Ningbo Zhejiang
China General Hospital of Northern Theater Command Shenyang Liaoning
China The First Affiliated Hospital of Wenzhou Medical University Wenzhou Zhejiang

Sponsors (1)

Lead Sponsor Collaborator
Lifetech Scientific (Shenzhen) Co., Ltd.

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Success rate of effective occlusion Effective occlusion was defined as: 180 days after the surgery, Transthoracic echocardiography (TTE) showed that the position and shape of the occluder were normal, and no horizontal atrial shunt was observed. Re-examination by Contrast transthoracic echocardiography (cTTE) showed no or only a small amount of right-to-left shunt, that is, no microvesicles or less than 10 microvesicles/frame in left heart cavity after Valsalva and resting state. 180 days after surgery
Secondary Success rate of occluder implantation technology The success of occluder implantation technology is defined as successful intraoperative implantation of occluder and immediate Echocardiography confirmed that the shape and position of the sealing device were appropriate, no new pericardial effusion or valve regurgitation was found, and the perioperative patients survived. 7 days after surgery
Secondary Success rate of surgical implantation of occlusion Successful occluder implantation was defined as successful implantation of occluder and routine postoperative hospitalization that there were no serious adverse events related to surgery. 7 days after surgery
Secondary Success rate of complete occlusion Complete occlusion was defined as the Transthoracic echocardiography (TTE) showing occlusion 180 days after surgery The position and shape of the apparatus were normal, and no horizontal atrial shunt was observed. The results of Contrast transthoracic echocardiography (cTTE) were reviewed there was no right-to-left shunt, that is, no microbubbles in the left heart cavity after Valsalva and resting state. 180 days after surgery
Secondary Success rate of effective occlusion Success rate of effective occlusion was defined as: Transthoracic echocardiography (TTE) showed the position and shape of the occluder 360 days after the operation Normal condition, no horizontal atrial shunt; Reexamination by Contrast transthoracic echocardiography (cTTE) showed no or few results in other words, there were no microbubbles or less than 10 microbubbles in the left heart cavity after Valsalva and resting state. 360 days after surgery
Secondary Recurrence or incidence of cryptogenic stroke during follow-up Cryptogenic stroke was defined as a new focal cerebral ischemia confirmed by neuroimaging (cranial MRI or CT), which was performed After extensive vascular, cardiac, and blood evaluation, non-atherosclerotic, cardiogenic, or arteriolar obliterators were identified Cerebral infarction caused by the diagnosis of exclusion. 360 days, 2 years, 3 years, 4 years, 5 years after surgery
Secondary All-cause mortality rate All-cause death is defined as death from any cause during the follow-up period. 360 days, 2 years, 3 years, 4 years, 5 years after surgery
Secondary Incidence of new atrial fibrillation and atrial flutter during follow-up period atrial fibrillation and atrial flutter 360 days, 2 years, 3 years, 4 years, 5 years after surgery
Secondary Incidence of device-related serious adverse events during follow-up (including device-related thrombosis, embolic stroke, and peripheral stroke) Arterial embolism, Atrioventricular block III degree, heart abrasion, infective endocarditis, severe hemolytic anemia, etc.); 360 days, 2 years, 3 years, 4 years, 5 years after surgery
Secondary Incidence of device defects. Device defects refer to unreasonable risks that may endanger human health and safety under normal use of medical devices in clinical trials, such as label errors, quality problems and failures. 360 days, 2 years, 3 years, 4 years, 5 years after surgery
See also
  Status Clinical Trial Phase
Completed NCT06192173 - Patent Foramen Ovale Closure in Migraine
Recruiting NCT04610463 - Evaluation of the Severity of Right to Left Shunt in PFO Patients After Systemic Embolism N/A
Completed NCT02882815 - Post Market Clinical Follow-up Study of IrisFITTM PFO (Patent Foramen Ovale) Occluder N/A
Completed NCT04604015 - RoBotic TCD Ultrasound BubbLe Study Compared to Transthoracic Echocardiography for Detection of Right to Left Shunt N/A
Active, not recruiting NCT04950192 - Philips Intracardiac Echocardiography (ICE) Clinical Registry
Not yet recruiting NCT04549272 - Assessment of Early Vascular Damage With Advanced Neuroimaging in Patient With Patent Foramen Ovale
Completed NCT02621528 - Lifetech CeraFlex™ Post-Market Surveillance Study N/A
Terminated NCT01018355 - The Effect of Device Closure of Patent Foramen Ovale in Elderly Patients With Crytogenic Stoke/TCI N/A
Completed NCT00831259 - Risk of Stroke in Pulmonary Embolism With a Patent Foramen Ovale (PFO) N/A
Not yet recruiting NCT05360771 - Study on the Safety and Effectiveness of the SnowyTM PFO Closure System N/A
Recruiting NCT05546320 - Comparison of the Effect of Medication Therapy in Alleviating Migraine With Patent Foramen Ovale Phase 4
Recruiting NCT05561660 - COMParison of the EffecT of dEvice Closure in Alleviating Migraine With PFO (COMPETE-2) Phase 4
Completed NCT03904277 - Does Patent Foramen Ovale Size Matter in Men and Women
Recruiting NCT06120270 - CeraFlex PFO Closure System PMCF Study
Terminated NCT01773252 - Right to Left Cardiac Shunt Detection Phase 3
Completed NCT01216423 - Pulmonary Embolism and Stroke in Patient With Patent Foramen Ovale N/A
Completed NCT03377465 - Biomarkers, Hemodynamic and Echocardiographic Predictors of Ischemic Strokes and Their Influence on the Course and Prognosis N/A
Active, not recruiting NCT04738071 - International Multicenter Patent foRamen OVale & strokE (IMPROVE) Registry
Not yet recruiting NCT06413147 - Long-term Procedural and Device Related Complications of PFO Closure
Not yet recruiting NCT06344494 - Cardiac Interventional ICE Imaging Trial N/A